scholarly journals Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study

2021 ◽  
Author(s):  
Woo Jung Kim ◽  
Seo Jung Lee ◽  
Eun Lee ◽  
Eun Young Lee ◽  
Kyungdo Han
Keyword(s):  
Fasting Glucose ◽  
Population Based ◽  
Glycemic Status ◽  
Glucose Levels ◽  
Onset Diabetes ◽  
Hazard Ratios ◽  
Incident Dementia ◽  
Dementia Prevention ◽  
Design And Methods ◽  
New Onset

Objective: To investigate the risk of incident dementia according to fasting glucose levels and presence of comorbidities. <p>Research Design and Methods:<b> </b>Using a health insurance claims database and the results of biennial health examinations in South Korea, we selected 8,400,950 subjects aged ≥40 years who underwent health examinations in 2009–2010. We followed them until 2016. Subjects’ baseline characteristics were categorized by presence of diabetes (yes/no) and glycemic status (normoglycemia/impaired fasting glucose (IFG)/new-onset diabetes/known diabetes (duration <5 years or ≥5 years). We estimated adjusted hazard ratios (aHRs) for dementia occurrence in each category. </p> <p>Results: During the observation period of 48,323,729 person-years, all-cause dementia developed in 353,392 (4.2%) subjects. Compared with normoglycemia, aHRs (95% confidence interval) were 1.01 (1.01–1.02) in IFG, 1.45 (1.44–1.47) in new-onset diabetes, 1.32 (1.30–1.33) in known diabetes <5 years, and 1.62 (1.60–1.64) in known diabetes ≥5 years. We found that associations between ischemic heart disease and chronic kidney disease with incident dementia were affected by the presence of diabetes. Ischemic stroke showed a greater association with incident dementia than diabetes. </p> Conclusions:<b> </b>Mild degrees of hyperglycemia and presence of comorbidities were associated with incident dementia. Intervention during the prodromal stage of a chronic disease (e.g., prediabetes) could be considered for dementia prevention.

scholarly journals Gender- and age-related differences of statin use on incident dementia in patients with rheumatoid arthritis: a Nationwide population-based cohort study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Tsung-Kun Lin ◽  
Jing-Yang Huang ◽  
Lung-Fa Pan ◽  
Gwo-Ping Jong
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Study ◽  
Subgroup Analysis ◽  
Cox Regression ◽  
Population Based ◽  
Age Related ◽  
Hazard Ratios ◽  
Incident Dementia ◽  
Gender And Age ◽  
New Onset

Abstract Background Some observational studies have found a significant association between the use of statin and a reduced risk of dementia. However, the results of these studies are unclear in patients with rheumatoid arthritis (RA). This study is to determine the association between the use of statins and the incidence of dementia according to sex and age-related differences in patients with RA. Methods We conducted a nationwide retrospective cohort study using the Taiwan Health Insurance Review and Assessment Service database (2003–2016). The primary outcome assessed was the risk of dementia by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Multiple Cox regression was used to estimate the adjusted hazard ratio of new-onset dementia. Subgroup analysis was also conducted. Results Among the 264,036 eligible patients with RA aged > 40 years, statin users were compared with non-statin users by propensity score matching at a ratio of 1:1 (25,764 in each group). However, no association was found between the use of statins and the risk of new-onset dementia (NOD) in patients with RA (HR: 1.01; 95% CI: 0.97–1.06). The subgroup analysis identified the use of statin as having a protective effect against developing NOD in male and older patients. Conclusion No association was observed between the use of a statin and the risk of NOD in patients with RA, including patients of both genders and aged 40–60 years, but these parameters were affected by gender and age. The decreased risk of NOD in patients with RA was greater among older male patients. Use of a statin in older male (> 60 years) patients with RA may be needed in clinical practice to prevent dementia.

scholarly journals Exercise and the Risk of Dementia in Patients with Newly Diagnosed Atrial Fibrillation: A Nationwide Population-Based Study

2021 ◽  
Vol 10 (14) ◽  
pp. 3126
Author(s):  
Jaehyun Lim ◽  
So-Ryoung Lee ◽  
Eue-Keun Choi ◽  
Kyung-Do Han ◽  
Jin-Hyung Jung ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Risk Reduction ◽  
Lower Risk ◽  
Population Based ◽  
Newly Diagnosed ◽  
Incident Dementia ◽  
Before And After ◽  
Korean National Health Insurance ◽  
New Diagnosis ◽  
New Onset

Background: It is unclear whether exercise would reduce dementia in patients with a new diagnosis of atrial fibrillation (AF). Therefore, we aimed to evaluate the association between the change in physical activity (PA) before and after new-onset AF and the risk of incident dementia. Methods: Using the Korean National Health Insurance Service database, we enrolled a total of 126,555 patients with newly diagnosed AF between 2010 and 2016, who underwent health examinations within two years before and after their diagnosis of AF. The patients were divided into four groups: persistent non-exercisers, exercise starters, exercise quitters, and exercise maintainers. Results: Based on a total of 396,503 person-years of follow-up, 5943 patients were diagnosed with dementia. Compared to persistent non-exercisers, exercise starters (adjusted hazard ratio (aHR) 0.87; 95% confidence interval (CI) 0.81–0.94), and exercise maintainers (aHR 0.66; 95% CI 0.61–0.72) showed a lower risk of incident dementia; however, the risk was similar in exercise quitters (aHR 0.98; 95% CI 0.92–1.05) (p-trend < 0.001). There was a J-shaped relationship between the dose of exercise and the risk of dementia, with the risk reduction maximized at 5–6 times per week of moderate-to-vigorous PA among exercise starters. Conclusion: Patients who initiated or continued regular exercise after diagnosis of AF were associated with a lower risk of dementia than persistent non-exercisers, with no risk reduction associated with exercise cessation. Our findings may provide evidence for the benefit of exercise prescription to patients with new-onset AF to prevent incident dementia regardless of their current exercise status.

scholarly journals Cross-Sectional and Longitudinal Association between Glycemic Status and Body Composition in Men: A Population-Based Study

Nutrients ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1878 ◽  
Author(s):  
Khaleal Almusaylim ◽  
Maggie Minett ◽  
Teresa Binkley ◽  
Tianna Beare ◽  
Bonny Specker
Keyword(s):  
Body Composition ◽  
Fasting Glucose ◽  
Population Based ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Glycemic Status ◽  
Cross Sectional ◽  
Population Based Study ◽  
Longitudinal Association ◽  
Total Body

This study sought to evaluate the associations between changes in glycemic status and changes in total body (TB), trunk, and appendicular fat (FM) and lean mass (LM) in men. A population-based study of men aged 20–66 years at baseline were included in cross-sectional (n = 430) and three-year longitudinal (n = 411) analyses. Prediabetes was defined as fasting glucose 100–125 mg/dL. Type 2 diabetes (T2D) was determined by: self-reported diabetes, current anti-diabetic drug use (insulin/oral hypoglycemic agents), fasting glucose (≥126 mg/dL), or non-fasting glucose (≥200 mg/dL). Body composition was evaluated by dual-energy X-ray absorptiometry. Longitudinal analyses showed that changes in TB FM and LM, and appendicular LM differed among glycemic groups. Normoglycemic men who converted to prediabetes lost more TB and appendicular LM than men who remained normoglycemic (all, p < 0.05). Normoglycemic or prediabetic men who developed T2D had a greater loss of TB and appendicular LM than men who remained normoglycemic (both, p < 0.05). T2D men had greater gains in TB FM and greater losses in TB and appendicular LM than men who remained normoglycemic (all, p < 0.05). Dysglycemia is associated with adverse changes in TB and appendicular LM.

Gender- and Age-related Differences of Statin Use on Incident Dementia in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study

2021 ◽  
Author(s):  
Tsung-Kun Lin ◽  
Jing-Yang Huang ◽  
Lung-Fa Pan ◽  
Gwo-Ping Jong
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Study ◽  
Subgroup Analysis ◽  
Older Patients ◽  
Cox Regression ◽  
Population Based ◽  
Age Related ◽  
Hazard Ratios ◽  
Gender And Age ◽  
New Onset

Abstract Background: Some observational studies have found a significant association between the use of statin and a reduced risk of dementia. However, the results of these studies are unclear in patients with rheumatoid arthritis (RA). This study is to determine the association between the use of statins and the incidence of dementia according to sex and age-related differences in patients with RA.Methods: We conducted a nationwide retrospective cohort study using the Taiwan Health Insurance Review and Assessment Service database (2003–2016). The primary outcome assessed was the risk of dementia by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Multiple Cox regression was used to estimate the adjusted hazard ratio of new-onset dementia. Subgroup analysis was also conducted.Results: Among the 264,036 eligible patients with RA aged > 40 years, statin users were compared with non-statin users by propensity score matching at a ratio of 1:1 (25,764 in each group). However, no association was found between the use of statins and the risk of new-onset dementia (NOD) in patients with RA (HR: 1.01; 95%CI: 0.97–1.06). The subgroup analysis identified the use of statin as having a protective effect against developing NOD in male and older patients.Conclusion: There is no association between the use of statin and the risk of NOD in patients with RA, but these parameters are influenced by gender and age. The decreased risk of NOD in patients with RA was greater among male and older patients. The use of statin in older male patients with RA for the prevention of dementia may be needed in clinical practice.

scholarly journals Predicting New Onset Diabetes Mellitus in Older Taiwanese: Metabolic Syndrome or Impaired Fasting Glucose?

2009 ◽  
Vol 16 (5) ◽  
pp. 627-632 ◽  
Author(s):  
Liang-Kung Chen ◽  
Li-Ning Peng ◽  
Ming-Hsien Lin ◽  
Hsiu-Yun Lai ◽  
Shinn-Jang Hwang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Onset Diabetes ◽  
New Onset Diabetes Mellitus ◽  
New Onset

scholarly journals The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Study

2019 ◽  
Vol 104 (10) ◽  
pp. 4594-4599 ◽  
Author(s):  
Dong-Hoe Koo ◽  
Kyung-Do Han ◽  
Cheol-Young Park
Keyword(s):  
Pancreatic Cancer ◽  
Glucose Level ◽  
Cumulative Incidence ◽  
Fasting Glucose ◽  
Population Based ◽  
Incidence Rates ◽  
Fasting Glucose Level ◽  
Glucose Levels ◽  
Level 1 ◽  
Level 2

Abstract Context It has been unclear whether the risk of pancreatic cancer is different according to glucose levels. Objective To determine the association between fasting glucose levels and pancreatic cancer risk using prospectively collected nationwide population-based cohort data in Korea. Design The National Health Insurance Service database of claims and preventive health check-up data recorded was used between 2009 and 2015. Setting and Participants A total of 25.4 million patients who had participated in a preventive health check-up between 2009 and 2013 were evaluated for pancreatic cancer incidence rates according to fasting glucose level. Main Outcomes Measures The cumulative incidence rate for pancreatic cancer was calculated after grouping according to fasting glucose levels as follows: (i) low normal (<90 mg/dL), (ii) high normal (90 to 99 mg/dL), (iii) prediabetes level 1 (100 to 109 mg/dL), (iv) prediabetes level 2 (110 to 125 mg/dL), (v) diabetes (≥126 mg/dL), and (vi) diabetes on anti-diabetic medications. Results The 5-year cumulative incidence rates (per 100,000) were as follows: (i) low normal = 32; (ii) high normal = 41; (iii) prediabetes level 1 = 50; (iv) prediabetes level 2 = 64; (v) diabetes = 75; and (vi) on anti-diabetic medications = 121. The risk of pancreatic cancer increased continuously with elevating fasting glucose levels (P < 0.0001). The incidence of pancreatic cancer increased significantly with increasing fasting blood glucose levels even after adjusting for age, sex, smoking, drinking, exercise, body mass index, and diabetes duration (P < 0.0001). Conclusions The cumulative incidence rate of pancreatic cancer significantly increased as the fasting glucose level elevated, even in populations with a normal glucose level range.

scholarly journals Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Yuanyuan Zhang ◽  
Chun Zhou ◽  
Jianping Li ◽  
Yan Zhang ◽  
Di Xie ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Fasting Glucose ◽  
Serum Alkaline Phosphatase ◽  
Positive Association ◽  
Trial Registration ◽  
Clinical Trial Registration ◽  
Onset Diabetes ◽  
Increased Risk ◽  
New Onset

Abstract Background The association between alkaline phosphatase (ALP) and incident diabetes remains uncertain. Our study aimed to investigate the prospective relation of serum ALP with the risk of new-onset diabetes, and explore possible effect modifiers, in hypertensive adults. Methods A total 14,393 hypertensive patients with available ALP measurements and without diabetes and liver disease at baseline were included from the China Stroke Primary Prevention Trial (CSPPT). The primary outcome was new-onset diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up, or fasting glucose ≥ 7.0 mmol/L at the exit visit. The secondary study outcome was new-onset impaired fasting glucose (IFG), defined as FG < 6.1 mmol/L at baseline and ≥ 6.1 but < 7.0 mmol/L at the exit visit. Results Over a median of 4.5 years follow-up, 1549 (10.8%) participants developed diabetes. Overall, there was a positive relation of serum ALP and the risk of new-onset diabetes (per SD increment, adjusted OR, 1.07; 95% CI: 1.01, 1.14) and new-onset IFG (per SD increment, adjusted OR, 1.07; 95% CI: 1.02, 1.14). Moreover, a stronger positive association between baseline ALP (per SD increment) with new-onset diabetes was found in participants with total homocysteine (tHcy) < 10 μmol/L (adjusted OR, 1.24; 95% CI: 1.10, 1.40 vs. ≥ 10 μmol/L: adjusted OR, 1.03; 95% CI: 0.96, 1.10; P-interaction = 0.007) or FG ≥ 5.9 mmol/L (adjusted OR, 1.16; 95% CI: 1.07, 1.27 vs. < 5.9 mmol/L: adjusted OR, 1.00; 95% CI: 0.93, 1.08; P-interaction = 0.009) Conclusions In this non-diabetic, hypertensive population, higher serum ALP was significantly associated with the increased risk of new-onset diabetes, especially in those with lower tHcy or higher FG levels. Clinical Trial Registration-URL Trial registration: NCT00794885 (clinicaltrials.gov). Retrospectively registered November 20, 2008.

New Onset Diabetes and Impaired Fasting Glucose After Liver Transplant: Risk Analysis and the Impact of Tacrolimus Dose

2014 ◽  
Vol 12 (1) ◽  
pp. 46-51 ◽  
Author(s):  
Kamran Bagheri Lankarani ◽  
◽  
Ahad Eshraghian ◽  
Saman Nikeghbalian ◽  
Parisa Janghorban ◽  
...  
Keyword(s):  
Risk Analysis ◽  
Liver Transplant ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Onset Diabetes ◽  
The Impact ◽  
Tacrolimus Dose ◽  
New Onset

scholarly journals Glucose Intolerance as Morbidity in Schizophrenia

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
V. Sibinovic ◽  
S. Raicevic-Sibinovic ◽  
V. Slavkovic
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Intolerance ◽  
Plasma Glucose ◽  
Laboratory Data ◽  
Elevated Serum ◽  
Antipsychotic Therapy ◽  
Family History Of Diabetes ◽  
Glucose Levels ◽  
Onset Diabetes ◽  
New Onset

This was an eight months prospective study.Study was active controlled in patients who were hospitalized in our Clinic. Schizophrenia was diagnosed by using PANSS scale and by using MKB 10 criteria. Laboratory data were measured at baseline, every month after therapy and at endpoint. Laboratory tests included glucose level in serum and OGTT, which were determined from blood, before breakfast and in the same hospital laboratory. Patients with family history of diabetes mellitus were excluded from the study.A total of 30 patients were recruited. the risperidone shows clinically insignificant effect on plasma glucose levels. Incidence of new onset diabetes was abaut 5% higher with olanzapine than risperidone, and the biggest increasing was in first three months. Elevated serum glucose levels have been shown with clozapine and dose-related effects were noted. We also found modest, but significant risk for increasing plasma glucose levels in patients with chlorpromazine medication. Lack of relationship between serum levels of zuclopentixol and plasma glucose has been shown. There are no apparent problems with sulpiride and with haloperidol. Medication with chlorpromazine did not show any significant modifications to blood glucose levels.The antipsychotics appear to be associated with the development of glucose intolerance, new-onset diabetes mellitus and exacerbation of existing diabetes mellitus. These disturbances in glucose metabolism have their own medical consequences. Thus, to minimize morbidity and mortality associated with the use of antipsychotic medications, close screening and monitoring for diabetes mellitus should become a priority for all clinicians treating schizophrenia patients receiving antipsychotic therapy.

Sign in / Sign up

Export Citation Format

Share Document